MedCity News September 25, 2024
The way venture capital firms invest in biotech startups has changed. Veteran VCs Chris Garabedian and Arjun Goyal offered their perspectives during a panel discussion at the World Medical Innovation Forum.
Biotech companies with novel molecules in clinical development require substantial sums of cash to finance that research. While venture capital firms continue to raise new funds to deploy across such investments, many companies that successfully landed financing a few years ago find it harder to raise money now.
Chris Garabedian, chairman and CEO of Xontogeny and venture portfolio manager of the Perceptive Advisors Xontogeny Ventures Fund, remembers that bullish time for biotech investing — he had a hand in some of those financing rounds. He acknowledges that startups have...
Today's Sponsors
Today's Sponsor